TMDX vs. LIVN, CNMD, ITGR, INMD, SLNO, BLFS, ZYXI, AXGN, FONR, and CUTR
Should you be buying TransMedics Group stock or one of its competitors? The main competitors of TransMedics Group include LivaNova (LIVN), CONMED (CNMD), Integer (ITGR), InMode (INMD), Soleno Therapeutics (SLNO), BioLife Solutions (BLFS), Zynex (ZYXI), AxoGen (AXGN), FONAR (FONR), and Cutera (CUTR). These companies are all part of the "electromedical equipment" industry.
TransMedics Group (NASDAQ:TMDX) and LivaNova (NASDAQ:LIVN) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, valuation and dividends.
LivaNova received 296 more outperform votes than TransMedics Group when rated by MarketBeat users. Likewise, 68.80% of users gave LivaNova an outperform vote while only 53.29% of users gave TransMedics Group an outperform vote.
LivaNova has a net margin of 1.53% compared to TransMedics Group's net margin of -10.36%. LivaNova's return on equity of 12.23% beat TransMedics Group's return on equity.
99.7% of TransMedics Group shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 6.7% of TransMedics Group shares are owned by insiders. Comparatively, 0.2% of LivaNova shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
LivaNova has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.
TransMedics Group has a beta of 1.99, suggesting that its share price is 99% more volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500.
TransMedics Group currently has a consensus price target of $102.00, suggesting a potential upside of 14.29%. LivaNova has a consensus price target of $64.40, suggesting a potential upside of 16.88%. Given LivaNova's higher possible upside, analysts plainly believe LivaNova is more favorable than TransMedics Group.
In the previous week, TransMedics Group had 2 more articles in the media than LivaNova. MarketBeat recorded 6 mentions for TransMedics Group and 4 mentions for LivaNova. TransMedics Group's average media sentiment score of 0.60 beat LivaNova's score of 0.20 indicating that TransMedics Group is being referred to more favorably in the media.
Summary
LivaNova beats TransMedics Group on 10 of the 18 factors compared between the two stocks.
Get TransMedics Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for TMDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TMDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TransMedics Group Competitors List
Related Companies and Tools
